Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®

NCT01075880 · clinicaltrials.gov ↗

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Rebif (Interferon beta-1a)

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

[object Object]